Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Human CD3 epsilon&CD3 gamma Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (Cat. No. CDG-H52W9) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), premium grade (Cat. No. CDE-M120a)) with an affinity constant of 39.6 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Human CD3 epsilon&CD3 gamma Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (Cat. No. CDG-H52W9) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Anti-Human CD3 antibody (UCHT1) with an affinity constant of 1.59 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Small Cell Lung Carcinoma; Neoplasms; Oligodendroglioma; Prostatic Neoplasms; Astrocytoma | Details |
| Elranatamab | PF-06863135; PF‑3135; RN-613 | Approved | Pfizer Inc | Elrexfio, ELREXFIO, ELREXFIO™ | United States | Multiple Myeloma | Pfizer Inc | 2023-08-14 | Bone Marrow Neoplasms; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
| Glofitamab | RG-6026; RO-7082859; RG6026-2; RO6026 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma | Details |
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TALVEY | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Breast Neoplasms; Neurofibrosarcoma; Prostatic Neoplasms; Neuroblastoma; Sarcoma; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Colonic Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
| Eluvixtamab | MT-114; AMG-330 | Phase 1 Clinical | Amgen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| BLYG-8824 | RG 6286; BLYG-8824; BLYG-8824A | Phase 1 Clinical | Genentech Inc | Colorectal Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
